Baseline characteristics by treatment group
| Characteristics . | Group . | P value . | ||||
|---|---|---|---|---|---|---|
| NT (A) . | HU (B) . | COMBI (C) . | IFN-α2 (D) . | HCs (E) . | ||
| Patients, n | 19 | 37 | 23 | 23 | 42 | |
| Sex | ||||||
| Female, n (%) | 9 (47.4) | 17 (45.9) | 11 (47.8) | 8 (34.8) | 17 (40.5) | NS |
| Age, y | E vs A, P = .002∗ | |||||
| Median (range) | 62 (38-79) | 74 (53-85) | 68 (47-79) | 65 (31-81) | 71(66-74) | E vs D, P = .001; B vs A + D, P = .001; B vs C, P = .01 |
| Disease length, wk† | ||||||
| Median (range) | 207 (0-1214) | 290 (13-2124) | 76 (16-1170) | 452 (44-1183) | NA | NS |
| Treatment length, wk | ||||||
| Median (range) | NA | 210 (13-1028) | 47 (13-369) | 186 (35-587) | NA | C vs B + D, P < .01∗ |
| Body mass index, kg/m2 | ||||||
| Mean (SD) | 25.4 (4.6) | 26.3 (4.1) | 26.3 (4.1) | 26.0 (3.9) | 24.9 (2.4) | NS |
| Smoking, n (%) | ||||||
| Current smoker | 3 (15.8) | 2 (5.4) | 3 (13.0) | 0 (0) | 1(2.4) | NS |
| Former smoker | 7 (36.8) | 17 (45.9) | 9 (39.1) | 10 (34.5) | 13 (31) | |
| Never smoker | 9 (47.4) | 18 (48.6) | 11 (47.8) | 12 (52.2) | 26(61.9) | |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (4.3) | 2 (4.8) | |
| Hypertension, n (%) | ||||||
| Yes | 10 (52.6) | 22 (59.5) | 14 (60.9) | 9 (39.1) | 16 (38.1) | |
| No | 9 (47.4) | 15 (40.5) | 9 (39.1) | 14 (60.9) | 26 (61.9) | NS |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 | |
| Comorbidity index‡ | ||||||
| Median (range) | 0 (0-9) | 1 (0-5) | 2 (0-8) | 1 (0-6) | 0 (0-4) | |
| n (%) | NS | |||||
| No comorbidities (CCI = 0) | 10 (52.6) | 11 (29.7) | 5 (21.7) | 10 (43.5) | 22 (52.4) | |
| Low burden (CCI = 1-2) | 7 (36.8) | 14 (37.8) | 13 (56.5) | 8 (34.8) | 16 (38.1) | |
| Moderate to high (CCI > 2) | 2 (10.5) | 12 (32.4) | 5 (21.7) | 5 (21.7) | 4 (9.5) | |
| Blood test | ||||||
| Leukocyte, ×109/L | ||||||
| Median (range) | 8.5 (5.2-20.0) | 6.7 (2.9-21.8) | 4.6 (2.9-7.3) | 4.1 (2.5-13.2) | 6.2 (4.5-9.4) | A vs C + D + E, P < .001∗ |
| A vs B, P = .03 | ||||||
| B vs C + D, P < .001 | ||||||
| E vs C + D, P < .001 | ||||||
| Hematocrit, % | ||||||
| Mean (SD) | 44 (4) | 42 (3) | 38 (5) | 42 (3) | 43 (3) | A vs C, P < .001§ |
| B vs C, P = .002 | ||||||
| C vs D, P = .002; C vs E, P < .001 | ||||||
| Thrombocyte, ×109/L | ||||||
| Median (range) | 415 (147-884) | 316 (120-635) | 288 (118-494) | 206 (113-820) | 227 (125-355) | A vs C, P = .03; A vs D, P < .01; A vs E, P < .001∗ |
| B vs D, P = .01; B vs E, P < .001 | ||||||
| eGFR | ||||||
| Mean (SD) | 83.8 (18.4) | 72.8 (12.2) | 75.2(15.3) | 85.1(12.2) | 73.1 (13.2) | B vs D, P = .02§ |
| JAK2 V617F allele burden‖, median (range) | 16 (0.11-49) | 8.4 (5.7-96) | 22 (0.42-59) | 6.65 (0.21-49) | 0 (0-0) | C vs D, P = .012∗ |
| E vs A + B + C + D, P < .001 | ||||||
| Characteristics . | Group . | P value . | ||||
|---|---|---|---|---|---|---|
| NT (A) . | HU (B) . | COMBI (C) . | IFN-α2 (D) . | HCs (E) . | ||
| Patients, n | 19 | 37 | 23 | 23 | 42 | |
| Sex | ||||||
| Female, n (%) | 9 (47.4) | 17 (45.9) | 11 (47.8) | 8 (34.8) | 17 (40.5) | NS |
| Age, y | E vs A, P = .002∗ | |||||
| Median (range) | 62 (38-79) | 74 (53-85) | 68 (47-79) | 65 (31-81) | 71(66-74) | E vs D, P = .001; B vs A + D, P = .001; B vs C, P = .01 |
| Disease length, wk† | ||||||
| Median (range) | 207 (0-1214) | 290 (13-2124) | 76 (16-1170) | 452 (44-1183) | NA | NS |
| Treatment length, wk | ||||||
| Median (range) | NA | 210 (13-1028) | 47 (13-369) | 186 (35-587) | NA | C vs B + D, P < .01∗ |
| Body mass index, kg/m2 | ||||||
| Mean (SD) | 25.4 (4.6) | 26.3 (4.1) | 26.3 (4.1) | 26.0 (3.9) | 24.9 (2.4) | NS |
| Smoking, n (%) | ||||||
| Current smoker | 3 (15.8) | 2 (5.4) | 3 (13.0) | 0 (0) | 1(2.4) | NS |
| Former smoker | 7 (36.8) | 17 (45.9) | 9 (39.1) | 10 (34.5) | 13 (31) | |
| Never smoker | 9 (47.4) | 18 (48.6) | 11 (47.8) | 12 (52.2) | 26(61.9) | |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 1 (4.3) | 2 (4.8) | |
| Hypertension, n (%) | ||||||
| Yes | 10 (52.6) | 22 (59.5) | 14 (60.9) | 9 (39.1) | 16 (38.1) | |
| No | 9 (47.4) | 15 (40.5) | 9 (39.1) | 14 (60.9) | 26 (61.9) | NS |
| Unknown | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 | |
| Comorbidity index‡ | ||||||
| Median (range) | 0 (0-9) | 1 (0-5) | 2 (0-8) | 1 (0-6) | 0 (0-4) | |
| n (%) | NS | |||||
| No comorbidities (CCI = 0) | 10 (52.6) | 11 (29.7) | 5 (21.7) | 10 (43.5) | 22 (52.4) | |
| Low burden (CCI = 1-2) | 7 (36.8) | 14 (37.8) | 13 (56.5) | 8 (34.8) | 16 (38.1) | |
| Moderate to high (CCI > 2) | 2 (10.5) | 12 (32.4) | 5 (21.7) | 5 (21.7) | 4 (9.5) | |
| Blood test | ||||||
| Leukocyte, ×109/L | ||||||
| Median (range) | 8.5 (5.2-20.0) | 6.7 (2.9-21.8) | 4.6 (2.9-7.3) | 4.1 (2.5-13.2) | 6.2 (4.5-9.4) | A vs C + D + E, P < .001∗ |
| A vs B, P = .03 | ||||||
| B vs C + D, P < .001 | ||||||
| E vs C + D, P < .001 | ||||||
| Hematocrit, % | ||||||
| Mean (SD) | 44 (4) | 42 (3) | 38 (5) | 42 (3) | 43 (3) | A vs C, P < .001§ |
| B vs C, P = .002 | ||||||
| C vs D, P = .002; C vs E, P < .001 | ||||||
| Thrombocyte, ×109/L | ||||||
| Median (range) | 415 (147-884) | 316 (120-635) | 288 (118-494) | 206 (113-820) | 227 (125-355) | A vs C, P = .03; A vs D, P < .01; A vs E, P < .001∗ |
| B vs D, P = .01; B vs E, P < .001 | ||||||
| eGFR | ||||||
| Mean (SD) | 83.8 (18.4) | 72.8 (12.2) | 75.2(15.3) | 85.1(12.2) | 73.1 (13.2) | B vs D, P = .02§ |
| JAK2 V617F allele burden‖, median (range) | 16 (0.11-49) | 8.4 (5.7-96) | 22 (0.42-59) | 6.65 (0.21-49) | 0 (0-0) | C vs D, P = .012∗ |
| E vs A + B + C + D, P < .001 | ||||||
CCI, Charlson Comorbidity Index; eGFR, estimated glomerular filtration rate; NA, not applicable; NS, not significant; SD, standard deviation.
Pairwise Wilcoxon rank sum test.
Weeks since diagnosis of PV.
Comorbidity scores were calculated using CCI.
Analysis of variance with post hoc Tukey honest significant difference test.
JAK2 V617F allele burden at sample time.